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37 Background: The aim of the present study was to investigate the effect of okra consumption on serum 
38 levels of lipid profiles and glycemic indices in Type 2 Diabetic (T2D) patients. 
39 Methods: The present study was a randomized, double-blinded clinical trial, carried out in Kerman, 
40 Iran. Sixty T2D patients were randomized into intervention and control groups, and received 10 g okra 
41 powder blended in 150 g conventional yogurt or conventional yogurt alone, along with dinner and lunch, 
42 for 8-weeks. Glycemic markers and lipid profile were assessed, as well as anthropometric measures, at 
43 the beginning and end of study. 
44 Results: The findings showed that 8-weeks okra consumption resulted in a significant decrease in 
45 fasting plasma glucose (-15.61±19.44 vs -3.40±24.78; P=0.02), HOMA-IR (-1.17±1.61 vs -0.14±1.64;
46 P=0.01), QUICKI (0.01±0.007 vs 0.00±0.01; P=0.004), triacylglycerol (-22.30±32.46 vs -3.86±30.57;
47 P=0.001), total-cholesterol (-10.23±10.36 vs -2.03±13.94; P=0.004), LDL-C (-8.15±10.01 vs -
48 2.31±9.37; P=0.02) and LDL-C/ HDL-C ratio (-0.28±0.37 vs -0.08±0.24; P=0.01). No significant 
49 difference was observed between groups in HDL-C, HbA1C, fasting insulin levels and anthropometric 
50 measures. 
51 Conclusion: The present study suggests that okra consumption can elicit improvements in lipid profile, 
52 as well as glycemic markers, among T2D patients. 











63 Type 2 diabetes (T2D) is one of the most prevalent non-communicable diseases worldwide, responsible 
64 for morbidity and early mortality, and can be characterized by hyperglycemia and insulin resistance 
65 (DeFronzo et al., 2015). The etiology of T2D is related to both genetic and environmental factors, 
66 including dietary pattern and physical activity (Zheng, Ley, & Hu, 2018). In addition to the negative 
67 health consequences of T2D, those affected are at an increased risk for stroke, cardiovascular disease, 
68 kidney disease, and retinopathy (Al-Saeed et al., 2016; Bril & Cusi, 2016; Pourmasoumi, Hadi, 
69 Najafgholizadeh, Joukar, & Mansour-Ghanaei, 2019); which is attributable to associated abnormal 
70 metabolic factors, such as hyperlipidemia and hyperglycemia (Group, 2010). Furthermore, T2D can 
71 lead to a reduction in quality of life and impose a huge economic burden on patients and health care 
72 systems (Seuring, Archangelidi, & Suhrcke, 2015). In addition, the typically prescribed anti-diabetic 
73 pharmacological agents often result in unfavorable side effects, which can limit the compliance of 
74 patients (Chaudhury et al., 2017; Hasani et al., 2019). In this regard, finding an effective approach or 
75 adjuvant remedy, which could reduce the cost of treatment, as well as decrease the adverse effects of 
76 pharmacological  agents,  remains  of  paramount  importance  (Karimian,  Hadi, Pourmasoumi, 
77 Najafgholizadeh, & Ghavami, 2019). In contemporary research and practice, medicinal plants have 
78 garnered interest, largely due to their purported beneficial effects on diseases, along with their overall 
79 lower cost and side effects in comparison to synthetic drugs (Clark, Ghaedi, Arab, Pourmasoumi, & 
80 Hadi, 2019; Pourmasoumi, Ghiasvand, et al., 2019). 
81 Okra (Abelmoschus esculentus (L.) (Moench)), also called lady’s finger, belonging to the Malvaceae 
82 family, is an annual plant which grows wildly in many countries worldwide (Amin, 2011). The 
83 components of okra are mainly carbohydrates, minerals, and vitamins, whilst also rich in bioactive 
84 ingredients, such as flavones, alkaloids, pectin, polysaccharides, and linoleic acid (C. Zhang et al., 
85 2018). It has been shown that okra possesses anti-tumor and anti-inflammatory properties and may 
86 confer a protective effect on the liver (Freitas et al., 2016; Z. Liao et al., 2019; Monte et al., 2014). 
87 Recently, experimental studies have shown the potential anti-diabetic role of okra in animal models 
88 (Sabitha, Ramachandran, Naveen, & Panneerselvam, 2011; Z. H. Tian et al., 2015). Although the 
89 animal studies have indicated a promising effect of okra on diabetic metabolic abnormalities (Huang, 
90 Wang, Lin, Lin, & Peng, 2017; Peng, Lin, Lin, Wang, & Huang, 2019), there is a paucity of data from 
91 human studies. Therefore, the present study was performed to investigate the effect of okra consumption 
92 on serum levels of lipid profile and glycemic indices in T2D patients. 
93 Methods:
94 Participants 
95 The present study was a double-blinded, single center, randomized clinical trial which was performed 
96 between 2015 to 2016. Participants were recruited from T2D diagnosed patients who were referred to 
97 Ali-Ebn-e-Abitalb, Kerman, Iran. T2D was diagnosed by an endocrinologist, in accordance with the 
98 American Diabetes Association Criteria (Association, 2013); fasting plasma glucose (FPG) ≥ 126
99 mg/dl, two-hour plasma glucose (2h-post prandial glucose) ≥ 200 mg/dl, and glycated hemoglobin 
100 (HbA1C) ≥ 6.5%. T2D patients aged 30 to 75 years old, with a Body mass index (BMI) between 20-
101 30, and duration of disease less than 5 years were included to the study. The patients were excluded if 
102 they also had an additional diagnosed chronic disease, such as cardiovascular disease, chronic kidney 
103 disease, non-alcoholic fatty liver, pulmonary disease, chronic inflammatory disease, or if they used 
104 insulin, were pregnant or lactating, were smokers, were following a specially prescribed diet, underwent 
105 herbal and/or medical treatment and/or supplemented with nutrients, antioxidants or omega 3 in the last 
106 6 months, or had a drastic change in their weight during the last 6 months.  The sample size was 
107 computed by using a formula which was suggested for clinical trial studies; based on data from previous 
108 studies (Erfani Majd, Tabandeh, Shahriari, & Soleimani, 2018; Li et al., 2017), and assuming type I 
109 error (α)=0.5, power 80%, and considering 20% attrition, the sample size was estimated to be 30 patients 
110 in each group. 
111 The present study was conducted in accordance with the Declaration of Helsinki and the study protocol 
112 was approved by the Ethical Committee of Isfahan University of Medical science (Ethical code: 
113 IR.MUI.REC.1396.2.121). It was also registered at the Iranian registry of clinical trials (register 
114 number: IRCT20190701044064N1). 
115 Study design 
116 Eligible participants were entered into a 2-week run-in period to refrain from possible medicinal herb 
117 intake. Firstly, the aim and nature of the study was explained, and informed consent was obtained from 
118 all participants. Subsequently, participants were matched, based on age and gender, and randomly 
119 assigned to the intervention or control group, to receive yogurt plus okra or yogurt alone, respectively, 
120 for 8-weeks. Randomization was performed by using a computer-generated random number sequence, 
121 and the process of randomization and allocation of participants was blinded from the researchers and 
122 participants until when the final data were analyzed.  Participants were instructed to consume okra 
123 powder blended in yogurt or yogurt alone with dinner and lunch-time meals for 8-weeks. The okra was 
124 purchased from an herbal drug market and its’ main ingredients are presented in Table 1. The okra 
125 group consumed 10 g okra powder (approximately equal to 100g fresh okra) blended in 150 g yogurt, 
126 whilst the placebo was given yogurt plus a consumable color, which made it similar in appearance to 
127 the okra plus yogurt. The intervention and control yogurt were similar as flavor and color, and were 
128 packaged and encoded by manufactures; therefore, blinding of researchers and participants was 
129 guaranteed until study cessation. Participants received their yogurt packs at the beginning of each week, 
130 and were also asked to bring back the empty packs to monitor participant adherence. In addition, 
131 participants were monitored through periodic phone interviewing to enhance the compliance of the 
132 intervention, as well as explore possible side-effects due to consuming okra. 
133 Assessment of dietary intake and physical activity 
134 In order to assess dietary intake, the participants were asked to record a 3-nonconsecutive-days (two 
135 week-days and one weekend) food record at the beginning and end of the trial. Daily macro nutrient 
136 intake of participants was analyzed from food record information by using Nutritionist IV software 
137 (First Databank, San Bruno, CA), modified for Iranian diets. Physical activity was also evaluated using 
138 the metabolic equivalent of task (MET) questionnaire (Ainsworth et al., 2000) at the beginning and end 
139 of the trial. In addition, participants were requested to maintain their habitual dietary and physical 
140 activity practices during the study. 
141 Assessment of biochemical and anthropometrics variables 
142 Anthropometric measures were evaluated, following an overnight fast, at the beginning and end of 
143 study. Weight and height of participants was measured by a digital scale (Seca, Hamburg, Germany) 
144 and a non-stretch tape measure (Seca, Hamburg, Germany), respectively, while they were wearing 
145 minimal cloths and unshod. BMI was estimated by dividing weight (Kg) by height squared (m2).
146 Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were also assessed using a mercury 
147 sphygmomanometer (ALPK2, Zhejiang, China; Datis Co, Tehran, Iran), twice for each person, and 
148 following 15 minutes of rest. The mean of the two measurements was recorded and entered for final 
149 analysis.
150 After 12 hours overnight fasting, a 10-milliliter blood sample was obtained from all participants at study 
151 commencement  and  after 8-weeks intervention.  FPG,  HbA1C,  triglyceride  (TG),  low-density 
152 lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were evaluated by 
153 an enzymatic method (Pars Azmun, Tehran. Iran). Fasting serum insulin levels were determined by 
154 ELISA methods (DiaMetra, Milano, Italy). Homeostatic model of assessment for insulin resistance 
155 (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI) were estimated in 
156 accordance with the suggested formulas (Matthews et al., 1985; Pisprasert, Ingram, Lopez-Davila, 
157 Munoz, & Garvey, 2013). 
158 Statistical analysis 
159 All statistical analyses were conducted using the Statistical Package for the Social Sciences (SPSS) 
160 software version 20 (SPSS Inc., Chicago, USA). Kolmogorov-Smirnov test was applied to examine the 
161 normality of data distribution. The intention-to-treat (ITT) analysis was performed for all participants 
162 who randomly assignment into the intervention and control groups. The method of ‘Last Observation
163 Carried Forward’ was used to dealing with missing data from dropout participants. To investigate the 
164 differences in general participant’s characteristics and dietary intake between intervention and control
165 groups, independent samples t-test was used. A paired T-Test was applied to determine the changes in 
166 each main outcome from baseline measures, in both intervention and control groups. In addition, 
167 analysis of covariance (ANCOVA), adjusted for age, sex, participant’s baseline energy intake, physical
168 activity, and body weight, was performed to compare the difference between change of outcomes of 
169 interest between the 2 groups during the study. Data were presented as mean ± standard deviation (SD) 
170 and a P value <0.05 was considered statistically significant. 
171 Results:
172 Figure 1 demonstrates the participant’s selection, the reasons for withdrawal, and number of patients
173 included in the final analysis. Briefly, 60 T2D patients met the inclusion criteria and were randomly 
174 assigned to intervention and control groups. During follow-up, 5 patients from the okra group [un-
175 willing to continue the study (n=2), lost to follow-up (n=3)] and 7 patients from the control group [un-
176 willing to continue the study (n=4), lost to follow-up (n=2), migration (n=1)] were lost to attrition. 
177 However, as ITT approach which was applied for dealing with information, data from all participants 
178 were analyzed. 
179 There were no significant differences in baseline characteristics, including anthropometrics measures, age, gender, 
180 duration of disease, blood pressure, glycemic indices, and physical activity, between the intervention and control 
groups (Table 2). In addition, according to information obtained from the 3-days food record, daily energy intake 181
182 as well as dietary macro and micronutrient ingredients were similar between intervention and control groups 
183 (Table 3). No adverse effect related to okra consumption was reported by patients throughout the study. 
184
We found that the consumption of okra significantly reduced FPG (-15.61±19.44 vs -3.40±24.78; P=0.02), 
185 HOMA-IR (-1.17±1.61 vs -0.14±1.64; P=0.01), QUICKI (0.01±0.007 vs 0.00±0.01; P=0.004), TG (-22.30±32.46 
186 vs -3.86±30.57; P=0.001), TC (-10.23±10.36 vs -2.03±13.94; P=0.004), LDL-C (-8.15±10.01 vs -2.31±9.37;
P=0.02) and LDL-C/ HDL-C ratio (-0.28±0.37 vs -0.08±0.24; P=0.01) in comparison to the control group. 187
188 However, we did not find any significant effect of okra intake on body weight (-0.50±2.04 vs -0.03±1.44; P=0.24), 
189 BMI (-0.17±0.95 vs -0.01±0.72; P=0.29), HDL-C (0.34±1.09 vs 0.31±2.32; P=0.76), HbA1C (-0.16±0.77 vs -
190 0.14±1.12; P=0.55), SBP (-
191
7
192 1.20±5.08 vs -0.53±5.29; P=0.41), DBP (-0.68±5.91 vs -0.23±3.98; P=0.78), and fasting insulin levels 
193 (-0.66±1.98 vs -0.02±1.65; P=0.23), when compared with the control group (Table 4).
195 The present study suggests that okra consumption for 8-weeks can be beneficial in modulating FPG, 
196 HOMA-IR, QUICKI as well as TG, TC, LDL-C, LDL-C/HDL-C ratio in diabetic patients. However, 
197 okra did not elicit any significant influence on HDL-C, HbA1C, blood pressure, fasting insulin levels, 
198 and body weight. 
199 Despite the innumerable strategies that are administrated for the prevention and treatment of T2D, it 
200 remains one of the most highly prevalent chronic diseases, globally. Herbal medicine, which has a 
201 historical background in many countries, such as those in the middle east and east Asian geographies, 
202 can be used as an alternative or adjuvant remedy for T2D. Indeed, the present study demonstrated that 
203 okra consumption yielded improvements in FPG, QUICKI and HOMA-IR. In accordance with these 
204 results, previous empirical studies have indicated that okra can improve the glucose and lipid metabolic 
205 parameters in T2D. A study conducted on diabetes -induced mice, via high-fat diet feeding combined 
206 with streptozotocin intraperitoneal injection, showed that 8-weeks administration with 200 or 400 
207 mg/kg body weight of a polysaccharide isolated from okra, resulted in an improved oral glucose 
208 tolerance test (Zhengzheng Liao et al., 2019). Another study revealed that oral glucose absorption in 24 
209 hours fasted rats reduced after okra intake (M. Khatun, Rahman, Biswas, & Islam, 2010). In the present 
210 study, a large reduction was observed in HOMA-IR and QUICKI; however, the decrease in fasting 
211 insulin levels did not reach significance. A study conducted by Fan et al. (Fan et al., 2014) showed that 
212 okra can significantly improve both insulin levels and HOMA-IR. It is conceivable that the discrepancy 
213 in our findings, vs. that of previous significant findings in insulin concentrations, are attributable to the 
214 model (human vs rodent) and varying okra intake. The quantity of okra used in the animal study was 
215 nearly 30g per body weight per day, which is equal to 1500 g/day okra consumption in a 50-kg person; 
216 which is drastically higher than the amount that used in this study (10 g/day), and indeed infeasible to 
217 be consumed in such quantities in humans. In addition to beneficial effects of okra on T2D; glycemic 
218 and lipid metabolic markers are shown to be improved in gestational diabetic rats (Z.-H. Tian et al., 
219 2015). 
220 The mechanism mediating the influence of okra in regulating glycemic status relevant markers is not 
221 well-understood. Okra may improve glucose tolerance and insulin sensitivity in T2D through 
222 ameliorating insulin signaling and increasing glucose utilization, as well as suppressing oxidative stress 
223 (L.-Y. Wang et al., 2012). It has also been demonstrated that okra polysaccharide can downregulate 
224 glucose and lipid levels through preventing PPAR signaling and liver X receptors (Wu, Shi, Wang, & 
225 Wang, 2016). In addition, okra contains abscisic acid, which has a hypoglycemic effect and might be 
226 capable of improving blood glucose levels (Daliu, Annunziata, Tenore, & Santini, 2019). Moreover, 
227 the anti-diabetic activity of okra could be attributed to its’ bioactive components, which might
228 contribute to inhibiting pancreatic islet cell apoptosis (Y. Zhang et al., 2014), suppressing α-amylase 
229 and α-glucosidase (Cui, Gu, Wang, Ouyang, & Wang, 2015; J.-L. Hu, Nie, Li, & Xie, 2013), anti-
230 inflammatory activity (J. Hu, Pang, Bai, Zheng, & Wu, 2013), activating the cAMP-PKA pathway (H. 
231 Wang, Shi, Bao, Li, & Wang, 2015), insulin enhancement (Ren et al., 2015), or even through pathways 
232 independent from insulin such as decreasing glucose uptake (Tang, Chen, Wang, & Sun, 2015), and 
233 downregulating glycogen phosphorylase mRNA expression (Xiao et al., 2012). 
234 The present study demonstrated a significant improvement in TG, TC, and LDL-C following 8-weeks 
235 okra administration. In line with our results, Ngoc et al. (Ngoc, Ngoc, Tran, & Phung, 2008) reported 
236 that okra, administered in doses of 30 g/kg body weight, decreased TC and TG concentration in 
237 hyperlipidemia induced mice. Another study indicated that okra (in ethanol extract form) can improve 
238 serum lipid levels in diet induced obese mice by its flavonoids, isoquercitrin and quercetin 3-O-
239 gentiobioside (Fan et al., 2014). The lipid management effect of okra might be attributed to decreases 
240 in lipid peroxidation through binding with bile-acid, prevention of bile acid reabsorption, and reducing 
241 liver cholesterol biosynthesis (Kahlon, Chapman, & Smith, 2007; Ngoc et al., 2008). The flavonoid 
242 content of okra can suppress the expression of nuclear receptor transcription factor PPARγ, which acts
243 as an important regulator in lipid and glucose homeostasis, respectively (Fan et al., 2014). In addition, 
244 the active components in okra can also reduce ROS and MDA, through enhancing the levels of SOD, 
245 GSH-Px, and CAT, which are considered the most important enzymes involved with the enzymatic 
246 antioxidant system (Wu et al., 2016). 
247 No adverse side-effects related with okra consumption were reported by patients throughout the 
248 duration of the study. Okra is a generally safe food which is widely used in cooking, although it is 
249 considered safe when used in food, there is lack of knowledge on the contraindication of okra intake in 
250 critically ill patients; therefore, it should be used with caution in clinical environments. Okra intake, 
251 when concurrent with metformin, might reduce the metformin absorption, thus, the food-drug 
252 interaction should be taken into account when okra is considered as an adjuvant treatment along with 
253 conventional pharmacological remedy (H. Khatun, Rahman, Biswas, & Islam, 2011). In addition, 
254 further studies are needed to examine minimum and maximum amount of okra needed to obtain optimal 
255 results on metabolic outcomes. 
256 To the best of the authors knowledge, the present study is the first clinical trial investigating the effect 
257 of okra on metabolic parameters in T2D adults. However, this study has several limitations which 
258 should be considered. First, the duration of study was relatively short, and it is possible that 8-weeks 
259 administration was not sufficient to yield significant beneficial effects in some variables, such as 
260 HbA1C and fasting insulin levels. However, even in this short duration, we could demonstrate a positive 
261 influence on lipid profiles and glycemic markers, which represents a promising finding for the treatment 
262 of T2D. Second, we were not able to independently analyze the all okra active components and only its 
263 main nutrients were analyzed; however, the all doses of okra were obtained from the same medical herb 
264 company, in batch form. The amount of bioactive components in okra, like other plant foods and herbs, 
265 are affected by the condition, storage, and cultivar, and therefore, these potential discrepancies must be 
266 considered. Third, although we tried to limit the effect of confounders, such as diet, it is possible that 
267 there were other variables, out of the control of the study, which may have influenced the results. 
268 Conclusion:
269 The present study suggests that okra consumption can improve lipid profiles, as well as insulin 
270 resistance and FPG concentration, among T2D patients. Okra consumption appears safe, with several 
271 therapeutic properties, with no reports of adverse effects in this study. Given these promising results, it 
272 is evident that okra may represent a viable adjuvant therapy in the treatment or management of T2D; 
273 however, further work is required to affirm the veracity of our findings. 
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Table 1. Okra powder nutrient components per 100 g 
Nutrients Amount 
Moisture 8.46 g 
Carbohydrate 50.24 g 
Protein 18.25 g 
Ash 10.57 g 
Crude Fiber 12.97 g 
Fat 2.49 g 
Flavonoid 2.6 mg 
Phenol 11.2 mg 
60
ndent samples t-test (2-tailed). 
-Abbreviations; BMI: Body Mass Index, F: Female, M: Male; HbA1C: Glycated hemoglobin; MET: 












e (year) 54.26±7.62 53.33±7.35 0.63
x (M/F) 9/21 7/23 0.78
dy weight (kg) 71.46±11.33 72.80±10.63 0.64
MI (kg/m2) 24.90±3.94 25.65±3.46 0.30
ration of disease 4.68±2.07 3.96±2.83 0.26
G (mg/dl) 182.54±51.11 183.36±58.43 0.94
A1C (%) 7.99±0.87 7.62±1.39 0.22
tolic blood pressure (mm Hg) 119.34±9.80 121.43±11.05 0.46
astolic blood pressure (mm Hg) 80±7.42 76±7.47 0.10
ysical activity (MET-h/day) at baseline 30.91±6.88 29.13±5.86 0.28






Table 3. Dietary intakes of study participants throughout the study. 
Variables Intervention group (N=35) Control group (N=35) P-value
Energy (Kcal/day) 
Before 2316±281 2274±314 0.58 
After 2188±274 2146±265 0.54 
Carbohydrate (gr/day) 
Before 334±84 297±101 0.12 
After 309±79 282±76 0.18 
Protein (gr/day) 
Before 81.1±11.7 78.2±10.7 0.30 
After 82.7±12.3 79.6±11.4 0.31 
Fat (gr/day) 
Before 68.7±10.6 70.8±10.7 0.44 
After 66.3±9.8 68.2±9.6 0.45 
MUFA (gr/day) 
Before 21.5±5.1 22.2±6.4 0.64 
After 21.2±4.6 21.8±5.9 0.63 
PUFA (gr/day) 
Before 18.1±7.4 17.4±6.9 0.70 
After 19.7±5.8 19.1±5.5 0.68 
Vitamin E (mg/day) 
Before 6.8±3.1 6.3±3.9 0.58 
After 6.7±3.7 6.4±3.7 0.75 
Zinc (mg/day) 
Before 9.7±1.8 9.1±2.5 0.34 
After 9.8±1.8 9.4±2.2 0.49 
Vitamin C (mg/day) 
Before 117±85 106±92 0.66 
After 113±73 109±88 0.86 
β carotene (μg/day)
Before 4521±3570 4260±4627 0.82 
After 4832±3604 4661±3688 0.87 
Dietary fiber (g/day) 
Before 12.24±4.16 11.83±5.31 0.74 
After 12.57±4.29 12.14±4.20 0.69 
MUFA: Mono-unsaturated fatty acid; PUFA: Poly-unsaturated fatty acid. 
17
43 44 45 46
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Un-willing to continue the study (n=2) 









Un-willing to continue the study (n=4) 
Lost to follow-up (n=2) 
Migration (n=1) 
Analyzed: (n=23) 
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